Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Annovis Bio, Inc. ANVS

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Apr 9, 2026 8-K 24 signals fired · top 15
Other
Fcpa Compliance Representation Nyse Listing Disclosure Market Price Definition Erisa Definition Or Compliance Statement No Broker Fees Representation Amendment Modification Waiver Clause Sanctions Compliance Representation Ipo Net Proceeds Disclosure Corporate Organization And Standing Representation Fractional Share Cash Payment Warrant Exercise Share Delivery Share Withholding Tax Settlement Institutional Investment Legal Opinion Methodology Disclosure
Core
Lead Asset Progress
Mar 25, 2026 8-K 1 signal fired
Core
Management Exodus
Mar 16, 2026 8-K 8 signals fired
Other
Enrollment Ahead Of Schedule Interim Data Positive Kol Endorsement Expanded Access Program Active
Core
Lead Asset Progress Indication Expansion Clinical Hold Patient Enrollment Velocity
Mar 13, 2026 10-K 77 signals fired · top 15
Other
Executive Educational Background Disclosure Warrant Valued Black Scholes Capital Raising Uncertainty Disclosed Net Loss Reported Cybersecurity Breach Reputational Harm Disclosure Nyse Listing Disclosure Nol Carryforward Expiration Disclosure Codm Segment Reporting Disclosure Nol Tax Credit Carryforward Coso Icfr Assessment Disclosure Valuation Allowance Deferred Tax Disclosure Personnel Cost Decrease Disclosure Interest Income Year Over Year Comparison
Core
Secondary Endpoint Mentioned
Biotech Risk
Trial Endpoint Missed
Feb 12, 2026 8-K 10 signals fired
Core
Clinical Trial Result Lead Asset Progress Indication Expansion Clinical Hold
Other
Enrollment Ahead Of Schedule Patient Retention High Fda Aligned Interim Data Positive
Biotech v3
Ind Submission Planned
Biotech Risk
Accelerated Approval
Jan 28, 2026 8-K 10 signals fired
Core
Clinical Trial Result Lead Asset Progress Indication Expansion Clinical Hold Patient Enrollment Velocity
Other
Enrollment Ahead Of Schedule Interim Data Positive Kol Endorsement Expanded Access Program Active Patient Retention High
Nov 12, 2025 10-Q 9 signals fired
Other
Net Loss Reported Warrant Valued Black Scholes Personnel Cost Decrease Disclosure Operating Lease Rent Expense Disclosed Interest Income Year Over Year Comparison Financing Activities Cash Flow Disclosure Liquidity Position Snapshot Disclosed Ipo Or Capital Raising Completion
Healthcare
Reimbursement Improving
Oct 28, 2025 8-K 10 signals fired
Other
Legal Opinion Scope Limitation Ipo Net Proceeds Disclosure Amendment Modification Waiver Clause Use Of Proceeds Disclosure Legal Opinion Methodology Disclosure Non Assignment Clause Closing Deliverables Specified Ipo Or Capital Raising Completion Corporate Authority Representation
Core
Lead Asset Progress